Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
Hemodialysis
Cinacalcet Does Not Up Risk for Severe Gastrointestinal Bleeding in Hemodialysis
Study is the largest to explore this potential safety issue to date.
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
Mineralocorticoid Receptor Antagonists May Lower Death Risk in Dialysis
Investigators reviewed 13 trials of spironolactone and 1 trial of eplerenone.
Study: Etelcalcetide Can Be Used Safely in Diabetic Nephropathy
Etelcalcetide use in patients with diabetic nephropathy might protect against development of adynamic bone disease, according to investigators.
Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
SARS-CoV-2 Antibody Response Durable for at Least 6 Months in Dialysis
Older adults and individuals with diabetes did not experience a faster decline in SARS-CoV-2 antibody titers, investigators found.
Psoriasis Treatment May Decrease Infection, Death Risk in End-Stage Kidney Disease
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
Erythropoietin May Up Risk for Hip Fracture in Hemodialysis Patients
Risk for hip fracture increased with EPO doses of 50 to 149, 150 to 299, and 300 or greater vs <50 units/kg/week
